Slide 1: The Breast Care Company
1 The Breast Care Company™ NASDAQ: ATOS WWW . ATOSSAGENETICS . COM J ANUARY 13, 2015 ©2015, A TOSSA G ENETICS , I NC . A LL R IGHTS R ESERVED .
Slide 2: Forward-Looking Statements
2 Some of the information presented herein may contain projections or other forward - looking statements regarding future events or the future financial performance of the Company . For example, our revenue forecast is a forward - looking statement . These statements are based on management’s curren
Slide 3: Corporate Summary
Atossa Genetics Inc. (IPO November 8, 2012) NASDAQ: ATOS Our Mission Prevent Breast Cancer Stock Price (Jan. 7 , 2015; 52 - Week Range) $1.27 ($.80 to $3.28) Shares Outstanding (Nov. 12, 2014) 24.6M Inside Ownership 5.7M (23%) Daily Volume (50 - day avg. at Jan. 7, 2015) 347,594 Market Capitalizatio
Slide 4: Current Breast Health Tools Inadequate
Current Breast Health Tools Inadequate 4 Breast Exam NOT Recommended! Imaging Mammography ONLY FOR women 50 - 74 Biopsy Only 1% Algorithms 70% have NO risk factors! 0 2 4 6 8 10 12 Women - Millions 105 MM U.S. Women
Slide 5: The Companion CarePath
The Companion CarePath 5 3. Patented p harmaceuticals for PBD 1. Patented collection devices 2. Proprietary PBD diagnostic services Note: Certain devices, tests and treatments are not cleared or approved, separately or as a system, for sale in the U.S.
Slide 6: Patented Collection Devices
6 Patented Collection Devices Non U.S. Market – ForeCYTE* Intended for the collection of NAF for cytological testing . Reusable, hand - held pump. CE Marked for Q1 European launch U.S. Market – FullCYTE Intended for the collection of ductal fluid for cytological testing. Single use only. Third party
Slide 7: Additional Patented Devices
7 Additional Patented Devices FullCYTE Microcatheters* ▪ Intended for ductal l avage – collects NAF from each duct. ▪ Also intended for targeted drug delivery. ▪ 2015 launch expected. *Not cleared or approved for sale in the U.S.
Slide 8: Laboratory Services
Laboratory Services Breast specimen cytology Pharmacogenomics 8
Slide 9: 2015 Sales & Marketing Strategy for Collection Devices
9 2015 Sales & Marketing Strategy for Collection Devices A Product/Territory/Partner Specific Program Additional Partners Will Be Sought Fisher HealthCare, McKesson, and Millennium currently under contract for ForeCYTE only.
Slide 10: 2015 Sales & Marketing Strategy for Diagnostic Services
10 2015 Sales & Marketing Strategy for Diagnostic Services A Service/Partner Specific Program Additional Services/Partners Will Be Sought Pharmacogenomics Cytology
Slide 11: Future Treatments by Atossa Genetics Will Be Local
11 Future Treatments by Atossa Genetics Will Be Local • Based on anti - estrogen treatments previously approved by FDA WITH • Localized treatment intended to reduce side effects PBD Treatment Options - Now and Future Current Treatment Option Is Oral Hormonal Therapy • Highly effective with >80% redu
Slide 12: 105M Women Potential Patient Population in US
105M Women (Stratify) 12 Potential 10 MM Patient Population - in US 91,765,000 10,000,000 3,000,000 235,000 All Women in the U.S.: 18 - 73 (105M) Healthy High Risk Survivors Breast Cancer
Slide 13: Income Statement
Income Statement YTD ($ 000’s) Sept. 30, 2014 Revenue – Services $37 Revenue – Products 0 Total Gross Revenue 37 Cost of Revenue (0) Gross Profit 37 Total Operating Exp. (8,880) Operating Loss (8,843) Net Loss $(8,845) 13
Slide 14: Balance Sheet – September 30, 2014
Balance Sheet – September 30, 2014 Assets ($000’s) Liabilities ($000’s) Current Assets: Current Liabilities: Cash $11,374 Accounts Pay. $439 Accts Rec. 29 Accrued Exp. 393 Prepd, Other 313 Other 708 Total 11,716 Total 1,540 Other Assets 691 Equity 15,233 Intangible 4,365 Total Assets $16,772 Total L
Slide 15: Capitalization
Capitalization Sept. 30 , 2014 (shares 000’s ) Common Stock 24,564 Preferred Stock 0 Warrants ($1.92) 6,033 Options Granted 3,464 Total Outstanding 34,061 15
Slide 16: Financial Highlights
16 x Forecasted 2015 Total Revenue of $8.0 M x 34.1 M shares outstanding provides leverage x No debt, no p referred s tock x Scalable contract m anufacturing and low - capital laboratory services Financial Highlights
Slide 17: Management – Comprehensive and Experienced
17 » Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer » Kyle Guse, CPA, Esq., MBA, CFO and General Counsel » Jelle Kylstra, M.D., MBA, VP Clinical R&D » Christopher Destro, Sr. VP Sales and Marketing » Scott Youmans, Sr. VP Operations » John Sawyer, Sr. VP Global Regulatory and QA » Pi
Slide 18: Investment Highlights
x 2015 Forecasted Total Revenue of $8.0 M from Two - Pronged Product - Service Financial Model x 2015 Pharmaceutical Clinical T rials D rive A dditional V alue x Multi - Billion Dollar Diagnostic and Therapeutic Markets - Women’s Health Driven x 148 Issued Patents Secure Shareholder Value x Experien
Slide 19: The Breast Care Company
19 The Breast Care Company™ NASDAQ: ATOS WWW . ATOSSAGENETICS . COM ©2015, A TOSSA G ENETICS , I NC . A LL R IGHTS R ESERVED .